Skip to content

KLRS KLRS Investment Proceeds

Investment Proceeds at other companies

Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$15.95M+43.6%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's investment proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's investment proceeds?
KLRS (KLRS) reported investment proceeds of $20M in Q1 2026.
How has KLRS's investment proceeds changed year-over-year?
KLRS's investment proceeds increased by 433.3% year-over-year, from $3.75M to $20M.
What is the long-term trend for KLRS's investment proceeds?
Over 3 years (2021 to 2025), KLRS's investment proceeds has grown at a -61.5% compound annual growth rate (CAGR), from $262.6M to $15M.
What does investment proceeds mean?
Cash received from sales, maturities, and redemptions of investment securities across all categories.